Endometrial carcinoma (EC) is the seventh most common malignancy in the world. Annually, EC develops in about 142,000 women and causes about 42,000 deaths [1] . Although the incidence of EC accounted for approximately 16% of gynecologic malignancies in Korea, its incidence has dramatically increased [2] . There were 132 registered cases of EC in 1991EC in , 239 in 1994EC in , 425 in 2000EC in and 862 in 2004. Moreover, the incidence of uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CC) has increased; its incidence accounted for 4% of all ECs in 2004 [3].
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clear cell and serous cell types. These tumors are not estrogen related, are seen in older patients, and carry poor prognosis.
UPSC, CC, and grade 3 endometrioid carcinomas (G3EC) are all considered high-grade endometrial carcinomas. Although high-grade ECs are less common than low-grade ECs, they account for a disproportionate number of deaths resulting from EC [5] . Regarding survival outcomes in patients with UPSC, CC, or G3EC, previous comparison studies between these histologic types have shown disagreement. Some studies have shown that UPSC and CC is associated with an unfavorable prognosis compared with G3EC [6, 7] . In contrast, a recent clinicopathologic analysis revealed no difference in outcome between UPSC and CC, and G3EC [8, 9] . This dichotomy likely stems from the limited and conflicting data available.
Recently, the International Federation of Gynecology and Obstetrics (FIGO) committee reviewed 20 years of data and revised the staging criteria for carcinoma of the endometrium [10] . In two large, register-based studies from USA, the 2009 revised FIGO staging system proved to be highly prognostic with appropriate changes [11, 12] . Thus, we performed restaging of the high-grade ECs from 1988 FIGO to those of 2009 FIGO and compared the clinicopathological data and the survival outcomes in patients with UPSC and CC, and G3EC.
MATERIALS AND METHODS

Patients
After Institutional Review Board approval, we retrospectively reviewed electronic medical records to identify patients who underwent treatment for FIGO stage IA-IV uterine cancers at Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea between November 1995 and September 2009. A total of 647 patients with endometrial cancer were treated during this time period. Patients with histologic types of G3EC, UPSC, and CC were selected. Endometrial carcinomas of mixed subtype were excluded from this study. We grouped the population into 2 histologic groups (I-II). Group I comprised 46 cases with UPSC and CC; group II comprised 51 cases with G3EC. All patients underwent simple hysterectomy, bilateral salpingo-oophorectomy. Comprehensive surgical staging, defined as pelvic washing, removal of all gross disease implants, omentectomy (in UPSC and CC), and systematic pelvic with or without paraaortic lymphadenectomy, was performed. Stage assignment was performed according to the revised FIGO surgical staging criteria reported in 2009 [13] . Information regarding treatment, including surgery, chemotherapy and/or radiation therapy and follow-up was collected. 
Progression-free survival and overall survival
Progression-free survival (PFS) was defined as the period between initial treatment and the occurrence of pathologicallyconfirmed relapse. In cases where tissue sample collection was difficult, recurrence was clinically assumed when the imaging studies highly suggested recurrence and tumor markers were elevated from the basal level. Overall survival (OS) was measured from the date of surgery until death caused by the disease.
Statistical methods
Frequency distributions between categorical variables among the groups were compared using the chi-square test. The Fisher's exact test was used if the expected frequency was <5. After the normality of the data was assessed, a twosample t-test or Mann-Whitney test was used for the analysis of differences, depending on the distribution of the continuous variables. The survival curves were calculated according to the Kaplan-Meier method with the log-rank test. The Cox proportional-hazards model was used for the multivariable analyses. Statistical analyses were performed with SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA). A p<0.05 was considered statistically significant, and all p-values were two-sided.
RESULTS
Ninety-seven cases of high-grade endometrial carcinoma were identified, including 35 UPSC, 11 CC, and 51 G3EC. The clinicopathological characteristics of the study population are listed in Table 1 (Table 2) .
With regard to the pathological characteristics, there were no differences in tumor size in the uterus, myometrial involve ment, lymphovascular space invasion, cervical stromal invasion, or lymph node metastases. However, disease spread beyond the uterus was significantly more frequent in UPSC and CC than in G3EC (41.3% vs.19.6%, p=0.020). There was no significant difference in the median age between those in the UPSC and CC group and G3EC group (61 vs. 57, p=0.092). The types of adjuvant therapy after primary surgery were unequally Overall, UPSC and CC was associated with poor OS outcome compared with G3EC, even after adjustment for 2009 FIGO stage and other clinicopathologic factors (Fig. 1) . In univariate analysis, histologic type UPSC and CC, 2009 FIGO stage of III-IV, and positivity for LVSI were negatively associated with PFS, as well as OS (Table 4 , Fig. 2 ). In multivariate analysis, these variables were consistently independent factors in OS (Table  4 ). There was no difference in PFS or OS when comparing UPSC and CC with G3EC after adjusting for 1988 FIGO stage and other clinicopathologic factors (Fig. 1) 
DISCUSSION
In this study, we found that the UPSC and CC had a worse prognosis than G3EC when patients were restaged using the 2009 FIGO staging system and this difference disappeared in patients with the 1988 FIGO staging system. Moreover, in Values are presented as number (%). CC, clear cell carcinoma; CT, chemotherapy; G3EC, with grade 3 endometrioid carcinoma; NS, not significant; RT, radiotherapy; UPSC, uterine papillary serous carcinoma. UPSC, CC, and G3EC have been identified as high-grade endometrial cancers and account for the majority of uterine cancer deaths [6] . Recently, Song et al. [14] suggested that UPSCs had similar clinicopathologic features compared to the patients with carcinosarcomas in the same study group. The 5-year survival rates of our patients and those from prior studies are summarized in Table 5 [6] [7] [8] [9] [15] [16] [17] [18] [19] [20] [21] . Some studies have shown that patients with UPSC or CC had a significantly poorer prognosis compared with that of patients with G3EC [6, 7, 20, 21] , while other studies revealed no difference in outcome between UPSC and CC, and G3EC [8, 9, [16] [17] [18] [19] . When compared to type I ECs, type II ECs are mostly represented by UPSC and CC, are more likely to present with metastatic disease at diagnosis, and have a poorer prognosis [8] . However, the molecular profile of G3EC has not yet been well characterized and G3EC does not clearly fit into either definition of type I or type II cancer. These controversies in classification have consequently generated conflicting results regarding the prognosis of these tumors.
In current study, comprehensive surgical staging was perfor med in both groups (G3EC vs. UPSC and CC) with pelvic and/or para-aortic lymph node dissection: 100% of the G3EC 
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and 91.1% of the UPSC and CC patients. Moreover, the same proportion of patients in both groups (G3EC, 84.8%; UPSC and CC, 84.4%) submitted to adjuvant treatment, although a greater propensity for chemotherapy was observed in UPSC and CC patients. Since UPSC shows similar behaviors and spread patterns to serous papillary carcinoma of the ovary, comprehensive surgical staging in UPSC patients was suggested to more reliably predict extrauterine spread [22] [23] [24] [25] . Recently, a variety of reports showed that platinum-based chemotherapy in combination with paclitaxel was the most effective adjuvant treatment modality in stage I-IV UPSC patients [26] [27] [28] [29] [30] . We observed that UPSC and CC had a worse prognosis than G3EC when restaged to the 2009 FIGO criteria. There were no differences in PFS and OS when comparing UPSC and CC with G3EC after adjusting for 1988 FIGO stage. Only 1988 FIGO high-stage disease had a strong negative impact on survival (HR, 8.99; 95% CI, 2.66 to 30.37; p<0.001). These results might be from that more patients with a poor prognosis were downstaged in a UPSC and CC group. The goal of combining the 1988 FIGO stages IA, IB, IIA, and IIIA with positive cytologyonly subgroups in the 2009 FIGO criteria was to create a more streamlined staging system that merged groups with similar survival rates [13] . Several studies have demonstrated that the 2009 FIGO staging system has improved prognosis predictions and is less complex than earlier FIGO versions [11, 12, 31] . However, some of these studies did not include serous or clear cell histologic types [10, 11] . In a study by Werner et al. [31] , which included both UPSC and CC, the majority of non-endometrioid tumors that were down-staged to 2009 [32] showed that disease-specific survival did not differ between stage IIIA cancer patients with positive cytology only (stage IIIA1) and those with uterine serosal invasion or adnexal spread (stage IIIA2). Moreover, patients who had stage IIIA1 disease with a non-endometrioid histologic type or LVSI (or both) had a significant frequency of extra-abdominal failure.
Recent relevant studies have reported the prognostic value of the 2009 FIGO staging criteria by comparing with the 1988 staging criteria of endometrial cancer. Lewin et al found the new staging criteria to appropriately delineate prognostic features [11] . On the other hand, Abu-Rustum et al. [33] evaluated their single-institution database and found that the revised system for stage I did not improve its predictive ability over the 1988 system. Seward et al. [34] evaluated the prognostic impact of these changes on the UPSC and reported that the 2009 FIGO criteria do not adequately delineate survival for UPSC in early-stage disease. They suggested that UPSC should continue to be staged with the more informative 1988 FIGO This study had some limitations. First, there may be a recall bias due to the retrospective design of the study. Second, the type of adjuvant therapy was unequally distributed. Third, the number of patients was relatively small, which may have affected the results. The observation from this small series calls for a large, multi-institutional investigation.
In conclusion, we observed that UPSC and CC patients had different prognosis according to the old and new FIGO staging system. Our results suggest that UPSC and CC compared with the G3EC may retain the 1988 FIGO to be a slightly better discriminator than 2009 FIGO. Further large studies to evaluate the prognostic significance of these new criteria are needed in the future.
